Learn about July 2025’s top biotech deals, featuring major collaborations in small molecules, antibodies, and drug delivery.

INNOVENT BIO (01801.HK) announced that in 1H25, the company achieved total product revenue exceeding RMB5.2 billion, ...

The demand for treatments targeting myeloproliferative disorders is rising sharply, propelled by several key factors that underscore the market's rob ...

Out-licensing drugs to multinational corporations is a natural step for Chinese biotechs, but the recent rise in deals is ...

These 10 stocks could mint the next wave of millionaires › IDEAYA Biosciences (NASDAQ:IDYA), a precision oncology company focused on developing targeted therapies for cancer, reported its ...

In July 2025, Clinuvel Inc. conducted a CUV105 study will assess the efficacy and safety of afamelanotide and NB-UVB light in ...

IDEAYA Biosciences' clinical trial progress, strong financials, and diversified pipeline signal long-term growth potential ...

As patent cliffs approach and new mechanisms gain ground, COPD drugs like HRS-9821 are fast becoming coveted assets.

Merck faces intense pressure from new global tariffs and a looming Keytruda patent expiration, but is fighting back with a $3 ...

Facing patent expiration for its blockbuster Keytruda, Merck aims to streamline operations with significant job cuts and ...

GSK signed a 12-asset licensing deal with Hengrui Pharma. Generic erosion on Vyvanse continued to hurt Takeda. Celltrion is ...